SpringWorks Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced that the U.S. Food ...
Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) ...
Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced a corporate restr...
Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment o...
Global biotechnology leader CSL announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one...
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely acti...
Merck known as MSD outside of the United States and Canada, announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating ziloverta...
Genentech, a member of the Roche Group, announced that a detailed analysis of its Phase III REGENCY trial of Gazyva® (obinutuzumab) in people with acti...
Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage...
Alumis Inc. (Nasdaq: ALMS) and ACELYRIN, Inc. (Nasdaq: SLRN) today announced a definitive merger agreement, creating a powerhouse in immunology-focused b...
Intuitive BioTechnologies LLC (IBT) is proud to announce they have added elemental analysis to their testing capabilities. IBT is now offering quantitati...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced its financial results for the first quarter ...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced its board of directors has unanimously authoriz...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clini...
© 2025 Biopharma Boardroom. All Rights Reserved.
